• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法国的机械循环支持治疗结果。

Results of mechanical circulatory support in France.

机构信息

Department of Heart Surgery, Service de chirurgie cardiaque, Nouvel Hôpital Civil, 67000 Strasbourg, France.

出版信息

Eur J Cardiothorac Surg. 2011 Sep;40(3):e112-7. doi: 10.1016/j.ejcts.2011.04.005. Epub 2011 May 18.

DOI:10.1016/j.ejcts.2011.04.005
PMID:21596580
Abstract

OBJECTIVE

To present the analyzed results on mechanical circulatory support (MCS) collected over a 7-year period, from 2000 to 2006, in France.

METHODS

A cohort of 520 patients was analyzed. Mean age was 43.7 ± 13.6 years. The main causes of cardiac failure were ischemic cardiomyopathy (39%), idiopathic dilated cardiomyopathy (41.3%), or myocarditis (6.4%). Bridge to transplantation was indicated in 87.8% of patients, bridge to recovery in 9%, while destination therapy was proposed in 3.2% of patients.

RESULTS

For patients in cardiogenic shock or advanced heart failure undergoing device implantation as bridge to transplantation or recovery (n=458), overall mortality was 39% (n=179). The main causes of mortality under MCS were multi-organ failure (MOF) (57.4%), neurological events (14.1%), or infections (11.9%). Heart transplantation was performed in 249 (54.3%) patients. The main causes of death following heart transplantation were primary graft failure (22.4%), MOF (14.3%), neurological event (14.3%), or infection (10.2%). Long-term survival in transplanted patients was 75 ± 2.8% at 1 year and 66 ± 3.4% at 5 years.

CONCLUSIONS

MCS is an essential therapeutic tool to save the life of young patients with cardiogenic shock or advanced cardiac failure. Early MCS implantation and the availability of a device that is adapted to the patient's clinical status are prerequisites for reducing overall mortality rates.

摘要

目的

呈现 2000 年至 2006 年期间法国收集的为期 7 年的机械循环支持(MCS)分析结果。

方法

对 520 例患者进行了分析。平均年龄为 43.7 ± 13.6 岁。心力衰竭的主要病因是缺血性心肌病(39%)、特发性扩张型心肌病(41.3%)或心肌炎(6.4%)。87.8%的患者被建议桥接移植,9%的患者桥接恢复,3.2%的患者被建议采用终末期治疗。

结果

对于因心源性休克或晚期心力衰竭而接受器械植入以桥接移植或恢复的患者(n=458),总体死亡率为 39%(n=179)。MCS 下死亡的主要原因是多器官衰竭(MOF)(57.4%)、神经系统事件(14.1%)或感染(11.9%)。249 例(54.3%)患者接受了心脏移植。心脏移植后死亡的主要原因是原发移植物衰竭(22.4%)、MOF(14.3%)、神经系统事件(14.3%)或感染(10.2%)。移植患者的 1 年和 5 年长期存活率分别为 75 ± 2.8%和 66 ± 3.4%。

结论

MCS 是挽救心源性休克或晚期心力衰竭年轻患者生命的重要治疗工具。早期 MCS 植入和拥有适合患者临床状况的器械是降低总体死亡率的前提。

相似文献

1
Results of mechanical circulatory support in France.法国的机械循环支持治疗结果。
Eur J Cardiothorac Surg. 2011 Sep;40(3):e112-7. doi: 10.1016/j.ejcts.2011.04.005. Epub 2011 May 18.
2
[Mechanical circulatory support: 15 years of experience in the Heart Center North Rhine-Westphalia].
Dtsch Med Wochenschr. 2004 Apr 8;129(15):800-4. doi: 10.1055/s-2004-822877.
3
Prediction of survival in patients with cardiogenic shock and multiorgan failure treated with biventricular assist device.应用双心室辅助装置治疗心原性休克伴多器官衰竭患者的生存预测。
ASAIO J. 2010 Jul-Aug;56(4):273-8. doi: 10.1097/MAT.0b013e3181dbefd0.
4
Permanent mechanical circulatory support in patients of advanced age.老年患者的永久性机械循环支持
Eur J Cardiothorac Surg. 2004 Apr;25(4):610-8. doi: 10.1016/j.ejcts.2004.01.017.
5
Single-centre experience with the Thoratec paracorporeal ventricular assist device for patients with primary cardiac failure.单中心使用Thoratec体外心室辅助装置治疗原发性心力衰竭患者的经验。
Arch Cardiovasc Dis. 2009 Jun-Jul;102(6-7):509-18. doi: 10.1016/j.acvd.2009.03.010. Epub 2009 May 23.
6
Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study.机械循环支持装置患者死亡和移植的预测因素:一项多机构研究。
J Heart Lung Transplant. 2009 Jan;28(1):44-50. doi: 10.1016/j.healun.2008.10.011. Epub 2008 Dec 12.
7
[Ventricular assist devices as bridge to heart transplantation in cardiogenic shock or terminal heart failure--12 years experience at the Sheba Medical Center].[心室辅助装置作为心源性休克或终末期心力衰竭患者心脏移植的过渡手段——舍巴医疗中心12年经验]
Harefuah. 2007 Nov;146(11):833-6, 911.
8
Emergency ventricular assist device: better survival rates in non-post cardiotomy-related cardiogenic shock.急诊心室辅助装置:在非心脏手术后的心源性休克中生存率更高。
Acta Chir Belg. 2001 Sep-Oct;101(5):226-31.
9
Outcome evaluation of the bridge-to-bridge concept in patients with cardiogenic shock.心源性休克患者桥接至桥接概念的结果评估。
Ann Thorac Surg. 2006 Jul;82(1):28-33. doi: 10.1016/j.athoracsur.2006.02.056.
10
Ventricular assist device support in children and adolescents as a bridge to heart transplantation.儿童和青少年使用心室辅助装置作为心脏移植的桥梁。
Ann Thorac Surg. 2006 Sep;82(3):926-32. doi: 10.1016/j.athoracsur.2006.02.087.

引用本文的文献

1
An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany.德国晚期慢性心力衰竭患者压力反射激活疗法的成本效用早期分析。
BMC Cardiovasc Disord. 2018 Aug 9;18(1):163. doi: 10.1186/s12872-018-0898-x.
2
Temporary assist device support for the right ventricle: pre-implant and post-implant challenges.右心室临时辅助装置支持:植入前和植入后的挑战。
Heart Fail Rev. 2018 Mar;23(2):157-171. doi: 10.1007/s10741-018-9678-z.
3
Experience with the SynCardia total artificial heart in a Canadian centre.
加拿大一家中心使用SynCardia全人工心脏的经验。
Can J Surg. 2017 Dec;60(6):375-379. doi: 10.1503/cjs.003617.
4
Extracorporeal life support for refractory ventricular tachycardia.体外生命支持治疗难治性室性心动过速。
Ann Transl Med. 2017 Feb;5(4):73. doi: 10.21037/atm.2017.01.39.
5
Minimally-invasive LVAD Implantation: State of the Art.微创左心室辅助装置植入术:当前技术水平
Curr Cardiol Rev. 2015;11(3):246-51. doi: 10.2174/1573403x1103150514151750.
6
Early clinical outcomes of new pediatric extracorporeal life support system (Endumo (2000) in neonates and infants.新型儿科体外生命支持系统(Endumo (2000))在新生儿和婴儿中的早期临床结果。
J Artif Organs. 2013 Sep;16(3):267-72. doi: 10.1007/s10047-013-0713-5. Epub 2013 May 30.